HRS-7058 + SHR-1316

HRS-7058 + SHR-1316 is an investigational combination therapy under clinical development for the treatment of advanced malignant solid tumors. HRS-7058 is a novel, highly selective small molecule inhibitor targeting the KRAS G12C mutation, which is implicated in various cancers. SHR-1316 (also known as adebrelimab) is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. The combination aims to leverage targeted inhibition of oncogenic KRAS signaling with immunotherapy-mediated enhancement of anti-tumor immunity. This regimen is being evaluated in phase II clinical trials for safety, tolerability, and efficacy in patients with advanced or locally advanced solid tumors harboring KRAS G12C mutations[1][5][7][9].